

Requires Authentication | Published online by De Gruyter | November 17, 2022

# Effect of short-term storage of blood samples on gene expression in lung cancer patients

*Eva Obermayr, Nina Koppensteiner, Nicole Heinzl, Eva Schuster, Barbara Holzer, Hannah Fabikan, Christoph Weinlinger, Oliver Illini, Maximilian J. Hochmair and Robert Zeillinger*

From the journal [Clinical Chemistry and Laboratory Medicine \(CCLM\)](#)

<https://doi.org/10.1515/cclm-2022-0738>



## Abstract

## Objectives

The stability of gene transcripts associated with the presence of circulating tumor cells (CTCs) has been predominantly studied in cultured cancer cell lines added to blood samples under artificial conditions. In the present study the effect of storage on CTC-related transcripts was assessed in blood samples taken from patients with non-small lung cancer (n=58).

## Methods

The blood samples were split in two equal parts to compare the gene expression with and without storage for 24 h at ambient temperature without preservative added. After enrichment using the microfluidic Parsortix<sup>®</sup> technology, the expression levels of selected genes were assessed using quantitative PCR following a gene-specific pre-amplification. The prognostic relevance of each gene in fresh and stored blood samples was evaluated using the R-package Survminer.

## Results

Some genes were either not affected (*TWIST1*, *CDH5*, *CK19*) or upregulated upon storage (*NANOG*, *MET*, *UCHL1*) but still associated with poor prognosis. In contrast, *ERBB3*, *PTHLH*, *EpCAM*, and *TERT* were no longer associated with the overall survival of the patients.

## Conclusions

The study demonstrates the surprising stability of CTC-related transcripts, which makes overnight shipping of native blood samples possible. Careful verification is required when using model systems – such as normal blood spiked with tumor cells – or other CTC-related markers, as individual transcripts may respond

differently to storage.

**Keywords:** [blood storage](#); [circulating tumor cells](#); [liquid biopsy](#); [molecular characterization](#); [preservative](#); [RNA stability](#)

**Corresponding author:** Eva Obermayr, Department of Obstetrics and Gynecology, Molecular Oncology Group, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria, Phone: +43 1 40400 78270, Fax: +43 1 40400 78320, E-mail: [eva.obermayr@muv.ac.at](mailto:eva.obermayr@muv.ac.at)

**Research funding:** This study received support from Angle plc. in the form of an in-kind contribution of Parsortix® PR1 devices and microfluidic separation cassettes. ANGLE plc. had no influence on the design of the study, in the collection, analysis, and interpretation of data.

**Author contributions:** All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

**Competing interests:** All authors declare no conflict of interest.

**Informed consent:** Informed consent was obtained from all individuals included in this study.

**Ethical approval:** The study was approved by the Ethic Committee of the Medical University of Vienna, Austria (EK366/2003 and EK2266/2018).

## References

1. <https://clinicaltrials.gov/ct2/results?term=circulating+tumor+cells&Search=Apply&recrs=a> (<https://clinicaltrials.gov/ct2/results?term=circulating+tumor+cells&Search=Apply&recrs=a>).
2. Zavridou, M, Mastoraki, S, Strati, A, Tzanikou, E, Chimonidou, M, Lianidou, E. Evaluation of preanalytical conditions and implementation of quality control steps for reliable gene expression and DNA methylation analyses in liquid biopsies. *Clin Chem* 2018;64:1522–33. <https://doi.org/10.1373/clinchem.2018.292318> (<https://doi.org/10.1373/clinchem.2018.292318>).
3. Obermayr, E, Agreiter, C, Schuster, E, Fabikan, H, Weinlinger, C, Baluchova, K, et al.. Molecular characterization of circulating tumor cells enriched by A microfluidic platform in patients with small-cell lung cancer. *Cells* 2019;8. <https://doi.org/10.3390/cells8080880> (<https://doi.org/10.3390/cells8080880>).
4. Obermayr, E, Maritschnegg, E, Agreiter, C, Pecha, N, Speiser, P, Helmy-Bader, S, et al.. Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. *Oncotarget* 2018;9:812–23. <https://doi.org/10.18632/oncotarget.22549> (<https://doi.org/10.18632/oncotarget.22549>).
5. Stathopoulou, A, Ntoulia, M, Perraki, M, Apostolaki, S, Mavroudis, D, Malamos, N, et al.. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. *Int J Cancer* 2006;119:1654–9. <https://doi.org/10.1002/ijc.22017> (<https://doi.org/10.1002/ijc.22017>).
6. Kassambara, A, Kosinski, M, Przemyslaw, B, Scheipl, F. *survminer: drawing survival curves using “ggplot2”*; 2020. Available from: <https://cran.r-project.org/package=survminer> (<https://cran.r-project.org/package=survminer>).
7. Obermayr, E, Koppensteiner, N, Heinzl, N, Schuster, E, Holzer, B, Fabikan, H, et al.. Cancer stem cell-like circulating tumor cells are prognostic in non-small cell lung cancer. *J Personalized Med* 2021;11. <https://doi.org/10.3390/jpm11111225> (<https://doi.org/10.3390/jpm11111225>).

8. Obermayr, E, Castillo-Tong, DC, Pils, D, Speiser, P, Braicu, I, Van Gorp, T, et al.. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance – a study of the OVCAD consortium. *Gynecol Oncol* 2013;128:15–21. <https://doi.org/10.1016/j.ygyno.2012.09.021> (<https://doi.org/10.1016/j.ygyno.2012.09.021>).
9. Das, K, Dumais, J, Basiaga, S, Krzyzanowski, GD. Carbon-13 nuclear magnetic resonance analysis of formaldehyde free preservatives. *Acta Histochem* 2013;115:481–6. <https://doi.org/10.1016/j.acthis.2012.11.004> (<https://doi.org/10.1016/j.acthis.2012.11.004>).
10. Qin, J, Alt, JR, Hunsley, BA, Williams, TL, Fernando, MR. Stabilization of circulating tumor cells in blood using a collection device with a preservative reagent. *Cancer Cell Int* 2014;14:23. <https://doi.org/10.1186/1475-2867-14-23> (<https://doi.org/10.1186/1475-2867-14-23>).
11. Das, K, Norton, SE, Alt, JR, Krzyzanowski, GD, Williams, TL, Fernando, MR. Stabilization of cellular RNA in blood during storage at room temperature: a comparison of cell-free RNA BCT((R)) with K3EDTA tubes. *Mol Diagn Ther* 2014;18:647–53. <https://doi.org/10.1007/s40291-014-0118-z> (<https://doi.org/10.1007/s40291-014-0118-z>).
12. Rodriguez-Lee, M, Kolatkar, A, McCormick, M, Dago, AD, Kendall, J, Carlsson, NA, et al.. Effect of blood collection tube type and time to processing on the enumeration and high-content characterization of circulating tumor cells using the high-definition single-cell assay. *Arch Pathol Lab Med* 2018;142:198–207. <https://doi.org/10.5858/arpa.2016-0483-0a> (<https://doi.org/10.5858/arpa.2016-0483-0a>).
13. Luk, AWS, Ma, Y, Ding, PN, Young, FP, Chua, W, Balakrishnar, B, et al.. CTC-mRNA (AR-V7) analysis from blood samples-impact of blood collection tube and storage time. *Int J Mol Sci* 2017;18. <https://doi.org/10.3390/ijms18051047> (<https://doi.org/10.3390/ijms18051047>).
14. Koch, C, Joosse, SA, Schneegans, S, Wilken, OJW, Janning, M, Loreth, D, et al.. Pre-analytical and analytical variables of label-independent enrichment and automated detection of circulating tumor cells in cancer patients. *Cancers (Basel)* 2020;12. <https://doi.org/10.3390/cancers12020442> (<https://doi.org/10.3390/cancers12020442>).
15. Hustler, A, Wishart, G, Templeman, A, Sales, EB, Torrecillas, SA, Mumford, K, et al.. Abstract 4880: Parsortix™ system: analytic performance evaluation using ovarian cancer cell lines. *Cancer Res* 2019;79:4880. <https://doi.org/10.1158/1538-7445.am2019-4880> (<https://doi.org/10.1158/1538-7445.am2019-4880>).
16. D'Alessandro, A, Liumbruno, G, Grazzini, G, Zolla, L. Red blood cell storage: the story so far. *Blood Transfus* 2010;8:82–8.
17. Hashemi Tayer, A, Amirizadeh, N, Ahmadinejad, M, Nikougoftar, M, Deyhim, MR, Zolfaghari, S. Procoagulant activity of red blood cell-derived microvesicles during red cell storage. *Transfus Med Hemotherapy* 2019;46:224–30. <https://doi.org/10.1159/000494367> (<https://doi.org/10.1159/000494367>).
18. Matthews, K, Myrand-Lapierre, ME, Ang, RR, Duffy, SP, Scott, MD, Ma, H. Microfluidic deformability analysis of the red cell storage lesion. *J Biomech* 2015;48:4065–72. <https://doi.org/10.1016/j.jbiomech.2015.10.002> (<https://doi.org/10.1016/j.jbiomech.2015.10.002>).
19. Sandlin, RD, Wong, KHK, Boneschansker, L, Carey, TR, Miller, KL, Rose, G, et al.. Preservative solution that stabilizes erythrocyte morphology and leukocyte viability under ambient conditions. *Sci Rep* 2017;7:5658. <https://doi.org/10.1038/s41598-017-05978-7> (<https://doi.org/10.1038/s41598-017-05978-7>).
20. Aceto, N, Bardia, A, Miyamoto, DT, Donaldson, MC, Wittner, BS, Spencer, JA, et al.. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. *Cell* 2014;158:1110–22. <https://doi.org/10.1016/j.cell.2014.07.013> (<https://doi.org/10.1016/j.cell.2014.07.013>).
21. Wong, KHK, Tessier, SN, Miyamoto, DT, Miller, KL, Bookstaver, LD, Carey, TR, et al.. Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. *Nat Commun* 2017;8:1733. <https://doi.org/10.1038/s41467-017-01705-y> (<https://doi.org/10.1038/s41467-017-01705-y>).

22. Payne, K, Brooks, JM, Taylor, GS, Batis, N, Noyvert, B, Pan, Y, et al.. Immediate sample fixation increases circulating tumour cell (CTC) capture and preserves phenotype in head and neck squamous cell carcinoma: towards a standardised approach to microfluidic CTC biomarker discovery. *Cancers (Basel)* 2021;13. <https://doi.org/10.3390/cancers13215519> (<https://doi.org/10.3390/cancers13215519>).
23. Apostolou, P, Ntanovasilis, DA, Pappasotiriou, I. Evaluation of a simple method for storage of blood samples that enables isolation of circulating tumor cells 96 h after sample collection. *J Biol Res (Thessalon)* 2017;24:11. <https://doi.org/10.1186/s40709-017-0068-9> (<https://doi.org/10.1186/s40709-017-0068-9>).
24. Mendelaar, PAJ, Kraan, J, Van, M, Zeune, LL, Terstappen, L, Oomen-de Hoop, E, et al.. Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients. *Mol Oncol* 2021;15:116–25. <https://doi.org/10.1002/1878-0261.12802> (<https://doi.org/10.1002/1878-0261.12802>).
25. Shaw Bagnall, J, Byun, S, Begum, S, Miyamoto, DT, Hecht, VC, Maheswaran, S, et al.. Deformability of tumor cells versus blood cells. *Sci Rep* 2015;5:18542. <https://doi.org/10.1038/srep18542> (<https://doi.org/10.1038/srep18542>).
26. Hasmim, M, Noman, MZ, Messai, Y, Bordereaux, D, Gros, G, Baud, V, et al.. Cutting edge: hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-beta1. *J Immunol* 2013;191:5802–6. <https://doi.org/10.4049/jimmunol.1302140> (<https://doi.org/10.4049/jimmunol.1302140>).
27. Nagata, A, Itoh, F, Sasho, A, Sugita, K, Suzuki, R, Hinata, H, et al.. The evolutionarily conserved deubiquitinase UBH1/UCH-L1 augments DAF7/TGF-beta signaling, inhibits dauer larva formation, and enhances lung tumorigenesis. *J Biol Chem* 2020;295:9105–20. <https://doi.org/10.1074/jbc.ra119.011222> (<https://doi.org/10.1074/jbc.ra119.011222>).
28. Mekki, MS, Mougel, A, Vincent, A, Paquet, C, Copin, MC, Leroy, C, et al.. Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors. *Oncotarget* 2018;9:27039–58. <https://doi.org/10.18632/oncotarget.25472> (<https://doi.org/10.18632/oncotarget.25472>).



## Supplementary Material

The online version of this article offers supplementary material (<https://doi.org/10.1515/cclm-2022-0738> (<https://doi.org/10.1515/cclm-2022-0738>)).

Received: 2022-07-29

Accepted: 2022-11-07

Published Online: 2022-11-17

© 2022 Walter de Gruyter GmbH, Berlin/Boston

— or —

PDF **€23.00**

## From the journal



Clinical Chemistry and Laboratory Medicine (CCLM)



Downloaded on 24.11.2022 from [frontend.live.degruyter.dgbricks.com/document/doi/10.1515/cclm-2022-0738/html](http://frontend.live.degruyter.dgbricks.com/document/doi/10.1515/cclm-2022-0738/html)

